VivoSim Labs (NASDAQ:VIVS) Announces Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) announced its quarterly earnings results on Wednesday. The company reported ($1.03) earnings per share for the quarter, FiscalAI reports. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The firm had revenue of $0.03 million during the quarter.

VivoSim Labs Price Performance

Shares of VivoSim Labs stock remained flat at $1.92 during trading hours on Wednesday. The company’s stock had a trading volume of 174,464 shares, compared to its average volume of 3,506,949. The company has a market capitalization of $5.01 million, a price-to-earnings ratio of -0.44 and a beta of 1.21. VivoSim Labs has a one year low of $1.41 and a one year high of $21.96. The company’s 50-day moving average is $2.08 and its two-hundred day moving average is $2.37.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.23% of the company’s stock.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.